

Package insert

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use AFLURIA safely and effectively. See full prescribing information for AFLURIA.

**AFLURIA, Influenza Virus Vaccine
Suspension for Intramuscular Injection
2011-2012 Formula
Initial U.S. Approval: 2007**

RECENT MAJOR CHANGES

Indications and Usage (1)	4/2011
Dosage and Administration (2.2)	4/2011

INDICATIONS AND USAGE

- AFLURIA is an inactivated influenza virus vaccine indicated for active immunization of persons ages 5 years and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. (1)
- This indication is based on the immune response elicited by AFLURIA; there have been no controlled clinical studies demonstrating a decrease in influenza disease after vaccination with AFLURIA. (14)

DOSAGE AND ADMINISTRATION

Children

- 5 years through 8 years of age** (0.5 mL dose, intramuscular injection): Previously unvaccinated children should receive two 0.5 mL doses, one on day 1 followed by another approximately 4 weeks later. (2.2)
Previously vaccinated children should receive only one 0.5 mL dose. (2.2)
- 9 years of age and older**
A single 0.5 mL dose for intramuscular injection. (2.2)

Adults

A single 0.5 mL dose for intramuscular injection. (2.2)

DOSAGE FORMS AND STRENGTHS

AFLURIA, a sterile suspension for intramuscular injection, is supplied in two presentations:

- 0.5 mL single-dose, pre-filled syringe, no preservative. (3)
- 5 mL multi-dose vial containing ten 0.5 mL doses. Thimerosal, a mercury derivative, is added as a preservative; each 0.5 mL dose contains 24.5 micrograms (mcg) of mercury. (3,11)

CONTRAINDICATIONS

- Hypersensitivity to eggs, neomycin, or polymyxin, or life-threatening reaction to previous influenza vaccination. (4)

WARNINGS AND PRECAUTIONS

- Administration of CSL's 2010 Southern Hemisphere influenza vaccine has been associated with increased postmarketing reports of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years. (5.1)
- If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA should be based on careful consideration of the potential benefits and risks. (5.2)
- Immunocompromised persons may have a diminished immune response to AFLURIA. (5.3)

ADVERSE REACTIONS

- In adults, the most common ($\geq 10\%$) local (injection-site) adverse reactions were tenderness, pain, redness, and swelling. The most common ($\geq 10\%$) systemic adverse reactions were headache, malaise, and muscle aches. (6)
- In children, the most common ($\geq 10\%$) local (injection-site) adverse reactions were pain, redness, and swelling. The most common ($\geq 10\%$) systemic adverse reactions were irritability, rhinitis, fever, cough, loss of appetite, vomiting/diarrhea, headache, muscle aches and sore throat. (6)
- Administration of CSL's 2010 Southern Hemisphere influenza vaccine has been associated with increased postmarketing reports of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. at 1-877-888-4231 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

DRUG INTERACTIONS

- Do not mix with any other vaccine in the same syringe or vial. (7.1)
- Immunosuppressive therapies may diminish the immune response to AFLURIA. (7.2)

USE IN SPECIFIC POPULATIONS

- Safety and effectiveness of AFLURIA have not been established in pregnant women or nursing mothers. (8.1, 8.3)
- AFLURIA is not indicated in children less than 5 years of age. (8.4)
- Antibody responses were lower in geriatric subjects than in younger subjects. (8.5)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 7/2011

Package insert

FULL PRESCRIBING INFORMATION: CONTENTS*

- 1 INDICATIONS AND USAGE**
- 2 DOSAGE AND ADMINISTRATION**
 - 2.1 Prior to Administration
 - 2.2 Administration
- 3 DOSAGE FORMS AND STRENGTHS**
- 4 CONTRAINDICATIONS**
- 5 WARNINGS AND PRECAUTIONS**
 - 5.1 Fever and Febrile Seizures
 - 5.2 Guillain-Barré Syndrome (GBS)
 - 5.3 Altered Immunocompetence
 - 5.4 Preventing and Managing Allergic Reactions
 - 5.5 Limitations of Vaccine Effectiveness
- 6 ADVERSE REACTIONS**
 - 6.1 Overall Adverse Reactions
 - 6.2 Safety Experience from Clinical Studies
 - 6.3 Postmarketing Experience
 - 6.4 Other Adverse Reactions Associated With Influenza Vaccination
- 7 DRUG INTERACTIONS**
 - 7.1 Concurrent Use With Other Vaccines
 - 7.2 Concurrent Use With Immunosuppressive Therapies

- 8 USE IN SPECIFIC POPULATIONS**
 - 8.1 Pregnancy
 - 8.3 Nursing Mothers
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
 - 12.1 Mechanism of Action
- 13 NONCLINICAL TOXICOLOGY**
 - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES**
 - 14.1 Immunogenicity in the Adult and Geriatric Populations
 - 14.2 Immunogenicity in a Pediatric Population
- 15 REFERENCES**
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
- 17 PATIENT COUNSELING INFORMATION**

* Sections or subsections omitted from the full prescribing information are not listed

Package insert

1 FULL PRESCRIBING INFORMATION

4 1 INDICATIONS AND USAGE

6 AFLURIA® is an inactivated influenza virus vaccine indicated for active immunization of
7 persons ages 5 years and older against influenza disease caused by influenza virus subtypes A
8 and type B present in the vaccine.

10 This indication is based on the immune response elicited by AFLURIA; there have been no
11 controlled clinical studies demonstrating a decrease in influenza disease after vaccination with
12 AFLURIA (*see Clinical Studies [14]*).

15 2 DOSAGE AND ADMINISTRATION

17 2.1 Prior to Administration

18 AFLURIA should be shaken thoroughly and then inspected visually for particulate matter and
19 discoloration prior to administration (*see Description [11]*), whenever suspension and
20 container permit. If either of these conditions exists, the vaccine should not be administered.
21 Any vaccine that has been frozen or is suspected of being frozen must not be used.

23 2.2 Administration

24 When using a preservative-free, single-dose syringe, shake the syringe thoroughly and
25 administer the dose immediately.

27 When using the multi-dose vial, shake the vial thoroughly before withdrawing each dose, and
28 administer the dose immediately. Between uses, store the vial at 2–8°C (36–46°F) (*see How
29 Supplied/Storage and Handling [16]*). Once the stopper has been pierced, the vial must be
30 discarded within 28 days.

32 *Children*

34 Children 5 years through 8 years of age not previously vaccinated with an influenza vaccine,
35 or vaccinated for the first time last season with only one dose, should receive two 0.5 mL
36 doses: one on day 1 followed by another approximately 4 weeks later. Children 5 years
37 through 8 years of age given two doses last season, or at least one dose two or more years ago,
38 should receive only one 0.5 mL dose.¹

40 Children 9 years of age and older should receive a single 0.5 mL dose.¹

42 Administer AFLURIA as an intramuscular injection in the deltoid muscle of the upper arm.

Package insert

44 **Adults**

45

46 AFLURIA should be administered as a single 0.5 mL intramuscular injection, preferably in
47 the deltoid muscle of the upper arm.

48

49

50 **3 DOSAGE FORMS AND STRENGTHS**

51

52 AFLURIA is a sterile suspension for intramuscular injection (*see Description [11]*).

53

54 AFLURIA is supplied in two presentations:

55

- 56 • 0.5 mL single-dose, pre-filled syringe, no preservative.
- 57 • 5 mL multi-dose vial. Thimerosal, a mercury derivative, is added as a preservative;
58 each 0.5 mL dose contains 24.5 mcg of mercury.

59

60

61 **4 CONTRAINDICATIONS**

62

63 AFLURIA is contraindicated in individuals with known hypersensitivity to eggs, neomycin,
64 or polymyxin, or in anyone who has had a life-threatening reaction to previous influenza
65 vaccination (*see Description [11]*).

66

67

68 **5 WARNINGS AND PRECAUTIONS**

69

70 **5.1 Fever and Febrile Seizures**

71 Administration of CSL's 2010 Southern Hemisphere influenza vaccine has been associated
72 with increased postmarketing reports of fever and febrile seizures in children predominantly
73 below the age of 5 years as compared to previous years.

74

75 **5.2 Guillain-Barré Syndrome (GBS)**

76 If GBS has occurred within 6 weeks of previous influenza vaccination, the decision to give
77 AFLURIA should be based on careful consideration of the potential benefits and risks.

78

79 **5.3 Altered Immunocompetence**

80 If AFLURIA is administered to immunocompromised persons, including those receiving
81 immunosuppressive therapy, the immune response may be diminished.

82

83 **5.4 Preventing and Managing Allergic Reactions**

84 Appropriate medical treatment and supervision must be available to manage possible
85 anaphylactic reactions following administration of the vaccine.

86

Package insert

87 **5.5 Limitations of Vaccine Effectiveness**

88 Vaccination with AFLURIA may not protect all individuals.
89
90

91 **6 ADVERSE REACTIONS**92 **6.1 Overall Adverse Reactions**

93 Serious allergic reactions, including anaphylactic shock, have been observed during
94 postmarketing surveillance in individuals receiving AFLURIA. Administration of CSL's
95 2010 Southern Hemisphere influenza vaccine [formulated to contain A/California/7/2009
96 (H1N1), A/Wisconsin/15/2009 (H3N2) and B/Brisbane/60/2008 (B Strain)] has been
97 associated with increased postmarketing reports of fever and febrile seizures in children
98 predominantly below the age of 5 years as compared to previous years (*see Warnings and*
99 *Precautions [5.1]*).
100

101
102 In adults, the most common local (injection-site) adverse reactions observed in clinical studies
103 with AFLURIA were tenderness, pain, redness (erythema), and swelling. The most common
104 systemic adverse reactions observed were headache, malaise, and muscle aches (myalgia).
105

106 In children, the most common local (injection-site) adverse reactions observed in a clinical
107 study with AFLURIA were pain, redness and swelling. The most common systemic adverse
108 reactions observed were irritability, rhinitis, fever, cough, loss of appetite, vomiting/diarrhea,
109 headache, muscle aches and sore throat. AFLURIA is not indicated in children less than 5
110 years of age. Fever, irritability, loss of appetite, and vomiting/diarrhea occurred more
111 frequently in children 6 months to less than 3 years of age as compared to older children in
112 one open label study. In another comparator-controlled trial, fever following the first dose of
113 Afluria was approximately 2.5 to 3 times more frequent in children less than 5 years of age as
114 compared to the U.S. licensed control.
115

116 **6.2 Safety Experience from Clinical Studies**

117 Because clinical studies are conducted under widely varying conditions, adverse reaction rates
118 observed in the clinical studies of a vaccine cannot be directly compared to rates in the
119 clinical studies of another vaccine and may not reflect the rates observed in clinical practice.
120

121 Clinical data for AFLURIA have been obtained in four clinical studies, three in adult
122 populations (Studies 1 to 3) and one in a pediatric population (Study 4) (*see Clinical Studies*
123 *[14]*). Clinical safety data are provided for two of the adult studies (Studies 1 and 2) and one
124 pediatric study (Study 4). Rates of solicited fever in children from a second pediatric study
125 (Study 5) are also provided.
126

127 A US study (Study 1) included 1,357 subjects for safety analysis, ages 18 to less than 65
128 years, randomized to receive AFLURIA (1,089 subjects) or placebo (268 subjects) (*see*

Package insert

129 *Clinical Studies [14] for study demographics*). There were no deaths or serious adverse
130 events reported in this study.

131
132 A UK study (Study 2) included 275 subjects, ages 65 years and older, randomized to receive
133 preservative-free AFLURIA (206 subjects) or a European-licensed trivalent inactivated
134 influenza vaccine as an active control (69 subjects) (*see Clinical Studies [14]*). There were no
135 deaths or serious adverse events reported in this study.

136
137 An open-label, uncontrolled study in children, conducted in Australia (Study 4), included 298
138 subjects, ages 6 months to less than 9 years. All subjects received preservative-free
139 AFLURIA administered as two doses, one month apart (*see Clinical Studies [14]*). Subjects
140 were subdivided into two age groups: children ages 6 months to less than 3 years (151
141 subjects) received two 0.25 mL doses of AFLURIA and children ages 3 years to less than 9
142 years (147 subjects) received two 0.5 mL doses of AFLURIA. There were no deaths or
143 vaccine-related serious adverse events reported in this study.

144
145 The safety assessment was identical for the two adult studies. Local (injection-site) and
146 systemic adverse events were solicited by completion of a symptom diary card for 5 days
147 post-vaccination (Table 1). Unsolicited adverse events were collected for 21 days post-
148 vaccination (Table 2). These unsolicited adverse events were reported either spontaneously or
149 when subjects were questioned about any changes in their health post-vaccination. All
150 adverse events are presented regardless of any treatment causality assigned by study
151 investigators.

152
153 In the open-label pediatric study (Study 4), solicited adverse events were recorded for up to 7
154 days (Table 3) and unsolicited adverse events were recorded for 30 days post-vaccination
155 (Table 4). Data are presented following each dose for each age group. All adverse events are
156 presented regardless of any treatment causality assigned by study investigators.

157
158 Rates of solicited fever in the seven days following vaccination with the 2009-2010
159 formulation of AFLURIA or another U.S. licensed influenza vaccine (manufactured by Sanofi
160 Pasteur, Inc.) in children 6 months to less than 18 years of age (Study 5) are shown in Table 5.

161

Package insert

162 **Table 1: Proportion of Subjects With Solicited Local or Systemic Adverse Events***
 163 **Within 5 Days After Administration of AFLURIA or Placebo, Irrespective of**
 164 **Causality† (Studies 1 and 2, Adult Populations)**
 165

Solicited Adverse Event	Study 1 Subjects ≥ 18 to < 65 years		Study 2 Subjects ≥ 65 years
	AFLURIA‡ n = 1089	Placebo§ n = 268	AFLURIA n = 206
Local			
Tenderness¶	60%	18%	34%
Pain¶	40%	9%	9%
Redness	16%	8%	23%
Swelling	9%	1%	11%
Bruising	5%	1%	4%
Systemic			
Headache	26%	26%	15%
Malaise	20%	19%	10%
Muscle aches	13%	9%	14%
Nausea	6%	9%	3%
Chills/Shivering	3%	2%	7%
Fever ≥ 37.7°C (99.9°F)	1%	1%	1%
Vomiting	1%	1%	0%

166 * In Study 1, 87% of solicited local and systemic adverse events were mild, 12% were moderate, and 1% were severe. In
 167 Study 2, 76.5% were mild, 20.5% were moderate, and 3% were severe. In both studies, most solicited local and systemic
 168 adverse events lasted no longer than 2 days.
 169 † Values rounded to the nearest whole percent.
 170 ‡ Includes subjects who received either the single-dose (preservative-free) or multi-dose formulation of AFLURIA.
 171 § Thimerosal-containing placebo.
 172 ¶ Tenderness defined as pain on touching.
 173 ¶ Pain defined as spontaneously painful without touch.

Package insert

174 **Table 2: Adverse Events* Reported Spontaneously by ≥ 1% of Subjects Within 21 Days**
 175 **After Administration of AFLURIA or Placebo, Irrespective of Causality†**
 176 **(Studies 1 and 2, Adult Populations)**
 177

Adverse Event	Study 1 Subjects ≥ 18 to < 65 years		Study 2 Subjects ≥ 65 years
	AFLURIA‡ n = 1089	Placebo§ n = 268	AFLURIA n = 206
Headache	8%	6%	8%
Nasal Congestion	1%	1%	7%
Cough	1%	0.4%	5%
Rhinorrhea	1%	1%	5%
Pharyngolaryngeal Pain	3%	1%	5%
Reactogenicity Event	3%	3%	0%
Diarrhea	2%	3%	1%
Back Pain	2%	0.4%	2%
Upper Respiratory Tract Infection	2%	1%	0.5%
Viral Infection	0.4%	1%	0%
Lower Respiratory Tract Infection	0%	0%	1%
Myalgia	1%	1%	1%
Muscle Spasms	0.4%	1%	0%

178 * In Study 1, 63% of unsolicited adverse events were mild, 35% were moderate, and 2% were severe. In Study 2, 47% were
 179 mild, 51% were moderate, and 3% were severe. In both studies, most unsolicited adverse events lasted no longer than 5 days.
 180 † Values rounded to the nearest whole percent.
 181 ‡ Includes subjects who received either the single-dose (preservative-free) or multi-dose formulation of AFLURIA.
 182 § Thimerosal-containing placebo.
 183

Package insert

184 **Table 3: Proportion of Subjects With Solicited Local or Systemic Adverse Events***
 185 **Within 7 Days After Administration of AFLURIA, Irrespective of Causality†**
 186 **(Study 4, Pediatric Population)**
 187

Solicited Adverse Event	Subjects ≥ 6 months to < 3 years (n = 151)‡		Subjects ≥ 3 years to < 9 years (n = 147)§	
	Dose 1	Dose 2	Dose 1	Dose 2
Local				
Pain	36%	37%	59%	62%
Erythema	36%	38%	37%	46%
Swelling	16%	21%	25%	27%
Systemic				
Irritability	48%	41%	20%	17%
Rhinitis	37%	48%	21%	29%
Fever¶	23%	23%	16%	8%
Cough	21%	32%	19%	19%
Loss of appetite	19%	24%	8%	5%
Vomiting/Diarrhea	15%	14%	8%	7%
Headache	2%¶	3%**	14%	11%
Myalgia	1%#	3%**	14%	8%
Sore throat	2%¶	5%**	8%	11%
Wheezing/Shortness of breath	3%	9%	3%	2%
Ear ache	3%**	3%#	4%	1%

* In Study 4, 78% of all local and systemic solicited events experienced by children ages 6 months to less than 3 years were mild, 19% were moderate and 3% were severe; 76% of all events experienced by children ages 3 years to less than 9 years were mild, 20% moderate and 4% severe. Severe pain was reported by < 1% of children ages 6 months to less than 3 years and 3% in children ages 3 years to less than 9 years. Severe fever (> 103.1°F axillary or > 104.0°F oral) was reported by < 1% of subjects in children ages 6 months to less than 3 years and 1% of subjects in children ages 3 years to less than 9 years.

† Values rounded to the nearest whole percent.

‡ Dosage in children 6 months to less than 3 years of age was 0.25 mL.

§ Dosage in children 3 years to less than 9 years of age was 0.5 mL.

¶ Axillary Temperature ≥ 37.5°C (99.5°F) or Oral Temperature ≥ 38.0°C (100.4°F).

¶ Data obtained from a total of 148 subjects.

Data obtained from a total of 149 subjects.

** Data obtained from a total of 150 subjects.

188

Package insert

189 **Table 4: Adverse Events* Reported Spontaneously by ≥ 5% of Subjects Within 30 Days**
 190 **After Administration of AFLURIA, Irrespective of Causality (Study 4,**
 191 **Pediatric Population)**
 192

Adverse Event	Subjects ≥ 6 months to < 3 years (n = 151) [†]		Subjects ≥ 3 to < 9 years (n = 147) [‡]	
	Dose 1	Dose 2	Dose 1	Dose 2
Nasopharyngitis	5.3%	7.9%	5.4%	5.4%
Rhinitis	13.2%	9.9%	6.8%	10.9%
Upper Respiratory Tract Infection	9.9%	7.3%	6.1%	6.1%
Irritability	3.3%	5.3%	0.7%	0.7%
Headache	1.3%	0.7%	6.1%	4.1%
Cough	10.6%	13.2%	10.9%	13.6%
Rhinorrhea	7.3%	6.0%	6.8%	4.8%
Teething	14.6%	9.9%	0.0%	0.0%
Vomiting	5.3%	2.6%	2.0%	2.7%
Influenza-like Illness	13.9%	10.6%	6.8%	3.4%
Pyrexia	2.6%	9.3%	2.7%	4.1%

* In Study 4, for both doses and both groups combined, 47% of unsolicited adverse events were mild, 42% were moderate, and 12% were severe.

[†] Dosage in children 6 months to less than 3 years of age was 0.25 mL.

[‡] Dosage in children 3 years to less than 9 years of age was 0.5 mL.

193
 194 **Table 5: Proportion of Subjects With Solicited Fever* Within 7 Days of Vaccination with**
 195 **AFLURIA or U.S. Licensed Comparator Vaccine (Study 5, Pediatric Population)**
 196

	Age Group						
	6 months to < 3 years [†]		3 to < 5 years [‡]		5 to < 9 years [§]		9 to < 18 years
	Dose 1	Dose 2	Dose 1	Dose 2	Dose 1	Dose 2	Dose 1
AFLURIA[¶]	37%	15%	32%	14%	16%	0%	6%
Comparator[¶]	14%	14%	11%	16%	9%	2%	4%

* Defined as ≥ 99.5°F axillary or ≥ 100.4°F orally after first or second vaccination.

[†] Dosage in subjects 6 months to less than 3 years was one or two 0.25 mL doses (depending on vaccination history) one month apart. Group sizes were n = 229 for AFLURIA dose 1, n = 228 for Comparator dose 1, n = 96 for AFLURIA dose 2, and n = 110 for Comparator dose 2.

[‡] Dosage in subjects 3 years to less than 5 years was one or two 0.5 mL doses (depending on vaccination history) one month apart. Group sizes were n = 91 for AFLURIA dose 1, n = 90 for Comparator dose 1, n = 29 for AFLURIA dose 2, and n = 25 for Comparator dose 2.

[§] Dosage in subjects 5 years to less than 9 years was one or two 0.5 mL doses (depending on vaccination history) one month apart. Group sizes were n = 161 for AFLURIA dose 1, n = 165 for Comparator dose 1, n = 39 for AFLURIA dose 2, and n = 53 for Comparator dose 2.

^{||} Dosage in subjects 9 years to less than 18 years was one 0.5 mL dose. Group sizes were n = 254 for AFLURIA dose 1 and n = 250 for Comparator dose 1.

[¶] 2009-2010 formulation [A/Brisbane/59/2007, IVR-148 (H1N1), A/Uruguay/716/2007, NYMC X-175C (H3N2) (an A/Brisbane/10/2007-like strain), and B/Brisbane/60/2008].

211
 212

Package insert

213 6.3 Postmarketing Experience

214 Because postmarketing reporting of adverse reactions is voluntary and from a population of
215 uncertain size, it is not always possible to reliably estimate their frequency or establish a
216 causal relationship to vaccine exposure. The adverse reactions described have been included
217 in this section because they: 1) represent reactions that are known to occur following
218 immunizations generally or influenza immunizations specifically; 2) are potentially serious;
219 or 3) have been reported frequently. These adverse reactions reflect experience in both
220 children and adults and include those identified during post-approval use of AFLURIA
221 outside the US since 1985.

222

223 Blood and lymphatic system disorders

224 Transient thrombocytopenia

225

226 Immune system disorders

227 Allergic reactions including anaphylactic shock and serum sickness

228

229 Nervous system disorders

230 Neuralgia, paresthesia, and convulsions (including febrile seizures); encephalopathy, neuritis
231 or neuropathy, transverse myelitis, and GBS

232

233 Vascular disorders

234 Vasculitis with transient renal involvement

235

236 Skin and subcutaneous tissue disorders

237 Pruritus, urticaria, and rash

238

239 6.4 Other Adverse Reactions Associated With Influenza Vaccination

240 Anaphylaxis has been reported after administration of AFLURIA. Egg protein can induce
241 immediate hypersensitivity reactions among persons who have severe egg allergy. Allergic
242 reactions include hives, angioedema, asthma, and systemic anaphylaxis (*see*
243 [Contraindications \[4\]](#)).

244

245 The 1976 swine influenza vaccine was associated with an increased frequency of GBS.
246 Evidence for a causal relation of GBS with subsequent vaccines prepared from other influenza
247 viruses is unclear. If influenza vaccine does pose a risk, it is probably slightly more than one
248 additional case per 1 million persons vaccinated.

249

250 Neurological disorders temporally associated with influenza vaccination, such as
251 encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus
252 neuropathy, have been reported.

253

254 Microscopic polyangiitis (vasculitis) has been reported temporally associated with influenza
255 vaccination.

Package insert

256

257

7 DRUG INTERACTIONS

259

7.1 Concurrent Use With Other Vaccines

261 There are no data to assess the concomitant administration of AFLURIA with other vaccines.
262 If AFLURIA is to be given at the same time as another injectable vaccine(s), the vaccine(s)
263 should be administered at different injection sites.

264

265 AFLURIA should not be mixed with any other vaccine in the same syringe or vial.

266

7.2 Concurrent Use With Immunosuppressive Therapies

268 The immunological response to AFLURIA may be diminished in individuals receiving
269 corticosteroid or immunosuppressive therapies.

270

271

8 USE IN SPECIFIC POPULATIONS

272

273

8.1 Pregnancy

275 Pregnancy Category C: Animal reproduction studies have not been conducted with
276 AFLURIA. It is also not known whether AFLURIA can cause fetal harm when administered
277 to a pregnant woman or can affect reproduction capacity. AFLURIA should be given to a
278 pregnant woman only if clearly needed.

279

8.3 Nursing Mothers

281 AFLURIA has not been evaluated in nursing mothers. It is not known whether AFLURIA is
282 excreted in human milk. Because many drugs are excreted in human milk, caution should be
283 exercised when AFLURIA is administered to a nursing woman.

284

8.4 Pediatric Use

286 AFLURIA is not indicated in children less than 5 years of age. The safety and
287 immunogenicity of AFLURIA was evaluated in 298 children between the ages of 6 months
288 and 9 years (Study 4). In this study the incidence of fever in children 6 months to < 3 years of
289 age following the first and second doses of AFLURIA was 23%. Among children 3 years to <
290 9 years of age the incidence was 16% following the first dose and 8% following the second
291 dose. The rates of solicited fever in the seven days following vaccination with the 2009-2010
292 NH formulation of AFLURIA have been compared to another U.S. licensed vaccine in
293 children 6 months to < 18 years of age (Study 5). In this study the incidence of fever in
294 children 6 months to < 3 years of age following the first and second doses of Afluria were
295 37% and 15%, respectively, as compared to 14% following each dose in the comparator
296 group. Among children 3 years to < 5 years of age, the incidence of fever following the first
297 and second doses of Afluria were 32% and 14%, respectively, as compared to 11% and 16%
298 in the comparator. Administration of CSL's 2010 Southern Hemisphere influenza vaccine has

Package insert

299 been associated with increased postmarketing reports of fever and febrile seizures in children
300 predominantly below the age of 5 years as compared to previous years (*see Adverse Reactions*
301 *[6.2]* and *Warnings and Precautions [5.1]*).

302

8.5 Geriatric Use

303 In four clinical studies, 343 subjects ages 65 years and older received AFLURIA.
304 Hemagglutination-inhibiting antibody responses in geriatric subjects were lower after
305 administration of AFLURIA in comparison to younger adult subjects (*see Clinical Studies*
306 *[14]*). Adverse event rates were generally similar in frequency to those reported in subjects
307 ages 18 to less than 65 years, although some differences were observed (*see Adverse*
308 *Reactions [6.2]*).

309

310

311

312

11 DESCRIPTION

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

AFLURIA, Influenza Virus Vaccine for intramuscular injection, is a sterile, clear, colorless to slightly opalescent suspension with some sediment that resuspends upon shaking to form a homogeneous suspension. AFLURIA is prepared from influenza virus propagated in the allantoic fluid of embryonated chicken eggs. Following harvest, the virus is purified in a sucrose density gradient using a continuous flow zonal centrifuge. The purified virus is inactivated with beta-propiolactone, and the virus particles are disrupted using sodium taurodeoxycholate to produce a “split virion”. The disrupted virus is further purified and suspended in a phosphate buffered isotonic solution.

AFLURIA is standardized according to USPHS requirements for the 2011-2012 influenza season and is formulated to contain 45 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the three influenza strains recommended for the 2011-2012 Northern Hemisphere influenza season: A/California/7/2009, NYMC X-181 (H1N1), A/Victoria/210/2009, NYMC X-187 (H3N2) (an A/Perth/16/2009-like strain), and B/Brisbane/60/2008.

Thimerosal, a mercury derivative, is not used in the manufacturing process for the single dose presentations; therefore these products contain no preservative. The multi-dose presentation contains thimerosal, added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury.

A single 0.5 mL dose of AFLURIA contains sodium chloride (4.1 mg), monobasic sodium phosphate (80 mcg), dibasic sodium phosphate (300 mcg), monobasic potassium phosphate (20 mcg), potassium chloride (20 mcg), and calcium chloride (1.5 mcg). From the manufacturing process, each 0.5 mL dose may also contain residual amounts of sodium taurodeoxycholate (≤ 10 ppm), ovalbumin (≤ 1 mcg), neomycin sulfate (≤ 3 nanograms [ng]), polymyxin B (≤ 0.5 ng), and beta-propiolactone (≤ 2 ng).

Package insert

341 The rubber tip cap and plunger used for the preservative-free, single-dose syringes and the
342 rubber stoppers used for the multi-dose vial contain no latex.

343
344

12 CLINICAL PHARMACOLOGY

345
346
347

12.1 Mechanism of Action

348 Influenza illness and its complications follow infection with influenza viruses. Global
349 surveillance of influenza identifies yearly antigenic variants. For example, since 1977
350 antigenic variants of influenza A (H1N1 and H3N2) and influenza B viruses have been in
351 global circulation. Specific levels of hemagglutination inhibition (HI) antibody titers post-
352 vaccination with inactivated influenza virus vaccine have not been correlated with protection
353 from influenza virus. In some human studies, antibody titers of 1:40 or greater have been
354 associated with protection from influenza illness in up to 50% of subjects.^{2,3}

355

356 Antibody against one influenza virus type or subtype confers limited or no protection against
357 another. Furthermore, antibody to one antigenic variant of influenza virus might not protect
358 against a new antigenic variant of the same type or subtype. Frequent development of
359 antigenic variants through antigenic drift is the virologic basis for seasonal epidemics and the
360 reason for the usual change to one or more new strains in each year's influenza vaccine.
361 Therefore, inactivated influenza vaccines are standardized to contain the HA of three strains
362 (i.e., typically two type A and one type B) representing the influenza viruses likely to be
363 circulating in the US during the upcoming winter.

364

365 Annual revaccination with the current vaccine is recommended because immunity declines
366 during the year after vaccination and circulating strains of influenza virus change from year to
367 year.¹

368

369

13 NONCLINICAL TOXICOLOGY

370

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

371
372
373 AFLURIA has not been evaluated for carcinogenic or mutagenic potential or for impairment
374 of fertility.

375

376

14 CLINICAL STUDIES

377

14.1 Immunogenicity in the Adult and Geriatric Populations

378
379
380 Three randomized, controlled clinical studies of AFLURIA have evaluated the immune
381 responses by measuring HI antibody titers to each virus strain in the vaccine. In these studies,
382 post-vaccination immunogenicity was evaluated on sera obtained 21 days after administration

Package insert

383 of AFLURIA. No controlled clinical studies demonstrating a decrease in influenza disease
384 after vaccination with AFLURIA have been performed.

385
386 The US study (Study 1) was a randomized, double-blinded, placebo-controlled, multicenter
387 study in healthy subjects ages 18 to less than 65 years. A total of 1,357 subjects were
388 vaccinated (1,089 subjects with AFLURIA and 268 with a thimerosal-containing placebo).
389 Subjects receiving AFLURIA were vaccinated using either a single-dose (preservative-free) or
390 multi-dose (one of three lots) formulation. The evaluable efficacy population consisted of
391 1,341 subjects (1,077 in the AFLURIA group and 264 in the placebo group) with complete
392 serological data who had not received any contraindicated medications before the post-
393 vaccination immunogenicity assessment. Among the evaluable efficacy population receiving
394 AFLURIA, 37.5% were men and 62.5% were women. The mean age of the entire evaluable
395 population receiving AFLURIA was 38 years; 73% were ages 18 to less than 50 years and
396 27% were ages 50 to less than 65 years. Additionally, 81% of AFLURIA recipients were
397 White, 12% Black, and 6% Asian.

398
399 In Study 1, the following co-primary immunogenicity endpoints were assessed: 1) the lower
400 bounds of the 2-sided 95% confidence intervals (CI) for the proportion of subjects with HI
401 antibody titers of 1:40 or greater after vaccination, which should exceed 70% for each vaccine
402 antigen strain; and 2) the lower bounds of the 2-sided 95% CI for rates of seroconversion
403 (defined as a 4-fold increase in post-vaccination HI antibody titers from pre-vaccination titers
404 of 1:10 or greater, or an increase in titers from less than 1:10 to 1:40 or greater), which should
405 exceed 40% for each vaccine antigen strain.

406
407 In subjects ages 18 to less than 65 years, serum HI antibody responses to AFLURIA met the
408 pre-specified co-primary endpoint criteria for all three virus strains (Table 6). Clinical lot-to-
409 lot consistency was demonstrated for the single-dose (preservative-free) and multi-dose
410 formulations of AFLURIA, showing that these formulations elicited similar immune
411 responses.

412
413 **Table 6: Study 1 – Serum HI Antibody Responses in Subjects ≥ 18 to < 65 Years**
414 **Receiving AFLURIA**
415

Treatment Arm	Number Enrolled/ Evaluable	Vaccine Strain	Seroconversion Rate* (95% CI)	HI Titer ≥ 1:40† (95% CI)
All active AFLURIA influenza vaccine formulations‡	1089/1077	H1N1	48.7% (45.6, 51.7)	97.8% (96.7, 98.6)
		H3N2	71.5% (68.7, 74.2)	99.9% (99.5, 100.0)
		B	69.7% (66.9, 72.5)	94.2% (92.7, 95.6)

Package insert

Placebo	270/264	H1N1	2.3% (0.8, 4.9)	74.6% (68.9, 79.8)
		H3N2	0.0% (N/A)	72.0% (66.1, 77.3)
		B	0.4% (< 0.1, 2.1)	47.0% (40.8, 53.2)

416 * Seroconversion rate is defined as a 4-fold increase in post-vaccination HI antibody titer from pre-vaccination titer $\geq 1:10$, or
 417 an increase in titer from $< 1:10$ to $\geq 1:40$. Lower bound of 95% CI for seroconversion should be $> 40\%$ for the study
 418 population.

419 † HI titer $\geq 1:40$ is defined as the proportion of subjects with a minimum post-vaccination HI antibody titer of 1:40. Lower
 420 bound of 95% CI for HI antibody titer $\geq 1:40$ should be $> 70\%$ for the study population.

421 ‡ Active formulations include aggregated results for the single-dose (preservative-free) and multi-dose formulations of
 422 AFLURIA.

423

424 The UK study (Study 2) was a randomized, controlled study that enrolled 275 healthy subjects
 425 ages 65 years and older. This study compared AFLURIA with a European-licensed trivalent
 426 inactivated influenza vaccine as an active control. The evaluable efficacy population
 427 consisted of 274 subjects (206 in the AFLURIA group and 68 in the control group). Among
 428 these subjects, 50% were men and 50% were women, with a mean age of 72 years (range: 65
 429 to 93 years).

430

431 The co-primary immunogenicity endpoints for the seroconversion rate and the proportion of
 432 subjects with a minimum post-vaccination HI antibody titer of 1:40 are presented in Table 7.

433

434 **Table 7: Study 2 – Serum HI Antibody Responses in Subjects ≥ 65 Years Receiving**
 435 **AFLURIA**

436

Number of Subjects	Vaccine Strain	Seroconversion Rate* (95% CI)	HI Titer $\geq 1:40$ † (95% CI)
206	H1N1	34.0% (27.5, 40.9)	85.0% (79.3, 89.5)
	H3N2	44.2% (37.3, 51.2)	99.5% (97.3, 100.0)
	B	45.6% (38.7, 52.7)	77.7% (71.4, 83.2)

437 * Seroconversion rate is defined as a 4-fold increase in post-vaccination HI antibody titer from pre-vaccination titer $\geq 1:10$, or
 438 an increase in titer from $< 1:10$ to $\geq 1:40$. Lower bound of 95% CI for seroconversion should be $> 30\%$ for the study
 439 population.

440 † HI titer $\geq 1:40$ is defined as the proportion of subjects with a minimum post-vaccination HI antibody titer of 1:40. Lower
 441 bound of 95% CI for HI antibody titer $\geq 1:40$ should be $> 60\%$ for the study population.

442

443 A second UK study (Study 3) was a randomized, controlled study that enrolled 406 healthy
 444 subjects ages 18 years and older (stratified by age from 18 to less than 60 years and 60 years
 445 and older). This study compared AFLURIA with a European-licensed trivalent inactivated
 446 influenza vaccine as an active control. In a post-hoc analysis of different age ranges, among
 447 subjects ages 18 to less than 65 years receiving AFLURIA (146 subjects), 47% were men and
 448 53% were women, with a mean age of 48 years for all subjects. Among subjects ages 65

Package insert

449 years and older receiving AFLURIA (60 subjects), 53% were men and 47% were women,
450 with a mean age of 71 years.

451
452 Analysis of serum HI antibody responses showed that the lower bound of the 95% CI for
453 subjects with HI antibody titers of 1:40 or greater after vaccination exceeded 70% for each
454 strain. HI antibody responses were lower in subjects, ages 65 years and older after
455 administration of AFLURIA. Serum HI antibody responses to the active control were similar
456 to those for AFLURIA in both age groups.

457

458 **14.2 Immunogenicity in a Pediatric Population**

459 An open-label, uncontrolled, multi-center study (Study 4) to evaluate the safety, tolerability
460 and immunogenicity of AFLURIA in children 6 months to 9 years of age was conducted in
461 Australia. The study subjects were subdivided into two groups dependent upon age at time of
462 enrollment. A total of 298 subjects were enrolled, including 151 subjects, 6 months to less
463 than 3 years (mean age 1.7 years with 51.0% females) and 147 subjects, 3 years to less than 9
464 years (mean age 5 years with 55.1% females).

465

466 Two doses of AFLURIA were administered to all subjects, with a 30 day interval between
467 each dose. Children ages 6 months to less than 3 years received two 0.25 mL doses of
468 AFLURIA. Children ages 3 years to less than 9 years were administered two 0.5 mL doses of
469 AFLURIA. Sera for immunological assessment were taken 30 days (± 3) following each
470 vaccination. Immunogenicity endpoints were the seroconversion rate and the proportion of
471 subjects with a minimum post-vaccination HI antibody titer of 1:40. AFLURIA is not
472 indicated in children less than 5 years of age. The results for each dose in children 5 years to
473 less than 9 years of age are presented in Table 8.

474

475 In children 5 years to less than 9 years of age, the vaccine met FDA acceptance criteria for
476 immunogenicity developed for healthy adults for all three influenza strains following two
477 doses. These criteria are: 1) that the lower bound of the 2-sided 95% CI for the seroconversion
478 rate should be at least 40%; and 2) the lower bound of the 2-sided 95% CI for the proportion
479 of subjects with a post-vaccination HI titer of $\geq 1:40$ should be at least 70%.

Package insert

480 **Table 8: Study 4 – Serum HI Antibody Responses in Subjects ≥ 5 Years to < 9**
 481 **Years Receiving AFLURIA**

482

	Vaccine Strain	Vaccine Dose	Seroconversion Rate* (lower 95% CI)	HI Titer ≥ 1:40† (lower 95% CI)
Subjects ≥ 5 years to < 9 years N = 82‡ N = 78§	H1N1	Dose 1	30.5% (> 21.6%)	31.7% (> 22.6%)
		Dose 2	96.2% (> 89.3%)	97.4% (> 91.1%)
	H3N2	Dose 1	68.3% (> 57.6%)	98.8% (> 93.4%)
		Dose 2	69.2% (> 58.3%)	100% (> 95.3%)
	B	Dose 1	42.7% (> 32.5%)	43.9% (> 33.7%)
		Dose 2	92.3% (> 84.2%)	93.6% (> 85.9%)

483

484 * Seroconversion rate is defined as a 4-fold increase in post-vaccination HI antibody titer from pre-vaccination titer ≥ 1:10, or
 485 an increase in titer from < 1:10 to ≥ 1:40. The lower 95% confidence limits were determined. Lower bound of 95% CI for
 486 seroconversion was taken as > 40% for the study population (as applied to adults 18 to 64 years of age).

487 † HI titer ≥ 1:40 is defined as the proportion of subjects with a minimum post-vaccination HI antibody titer of 1:40. The
 488 lower 95% confidence limits were determined. Lower bound of 95% CI for HI antibody titer ≥ 1:40 was taken as > 70% for
 489 the study population (as applied to adults 18 to 64 years of age).

490 ‡ Evaluable population post-dose 1.

491 § Evaluable population post-dose 2.

492

Package insert

493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508

15 REFERENCES

1. Centers for Disease Control and Prevention. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2009;58 (RR-8):1-46.
2. Hannoun C, Megas F, Piercy J. Immunogenicity and Protective Efficacy of Influenza Vaccination. *Virus Res* 2004;103:133-138.
3. Hobson D, Curry RL, Beare AS, et al. The Role of Serum Hemagglutination-Inhibiting Antibody in Protection Against Challenge Infection with Influenza A2 and B Viruses. *J Hyg Camb* 1972;70:767-777.

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied	NDC Number
Package of ten 0.5 mL single-dose, prefilled syringes without needles	33332-011-01
Package of one 5 mL multi-dose vial, which contains ten 0.5 mL doses	33332-111-10

509
510
511
512

Store refrigerated at 2–8°C (36–46°F). Do not freeze. Protect from light. Do not use AFLURIA beyond the expiration date printed on the label.

17 PATIENT COUNSELING INFORMATION

513
514
515
516
517
518
519
520
521
522

- Inform the patient that AFLURIA is an inactivated vaccine that cannot cause influenza but stimulates the immune system to produce antibodies that protect against influenza. The full effect of the vaccine is generally achieved approximately 3 weeks after vaccination. Annual revaccination is recommended.
- Instruct the patient to report any severe or unusual adverse reactions to their healthcare provider.



Package insert

523
524
525
526
527
528
529
530
531
532
533
534
535
536
537

Manufactured by:
CSL Limited
Parkville, Victoria, 3052, Australia
US License No. 1764

Distributed by:
Merck Sharp & Dohme Corp., a subsidiary of
MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

AFLURIA is a registered trademark of CSL Limited. CSL Biotherapies is a division of CSL Limited.